Q-omics provides the consensus-scored ZNF625 profile across patient tissues and cancer cell-line models. ZNF625 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF625 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZNF625 RNA expression shows 20,685 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, KICH, and UVM as cancer lineages where ZNF625 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF625 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF625 survival associations across molecular data types. ZNF625 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF625 RNA expression–survival associations across cancer types. High ZNF625 expression shows unfavorable associations in LGG and UVM, but favorable associations in SCLC, HNSC, KIRP and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF625 RNA expression.
This table summarizes ZNF625 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF625. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF625 shows lower tumor expression in KICH and COAD and higher tumor expression in BRCA, LIHC, BLCA and LUAD. The KICH box plot shows higher ZNF625 RNA expression in normal versus tumor tissue (log2 FC = −0.344, t-test p < 0.001).
This table shows molecular features associated with ZNF625 in patient tissues and cancer cell lines. In patient samples, ZNF625 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF625 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
